Skip to content
Clinical Trials – home
LatviaBack to Latvia

Clinical trials in Sigulda – page 5

116 clinical trials in Sigulda, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Sigulda at a glance
116
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

116 trials in Sigulda

Open in trial search

Study Comparing AVT16 and Vedolizumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Alvotech Swiss AG

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Roflumilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Study Comparing BP11 and Omalizumab for Patients with Chronic Spontaneous Urticaria Resistant to H1 Antihistamines

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Curateq Biologics Private Limited

Dermatitis atopic

Not recruiting

Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Study on the Effects of Semaglutide on Diabetic Eye Disease in People with Type 2 Diabetes

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Psoriatic arthropathy

Not recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib, Placebo, and Adalimumab for Patients with Moderate to Severe Rheumatoid Arthritis on Stable Methotrexate Treatment

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometriosis

Not recruiting

Study on the Effectiveness and Safety of OG-6219 and Naproxen Sodium for Women Aged 18-49 with Moderate to Severe Endometriosis Pain

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years
  • Substances:FOR-6219
  • Sponsor:Organon LLC

Other cities in Latvia

The busiest research cities in the country

All 18 cities in Latvia

Clinical research in Sigulda

What the registry says about research in the country

01 Diabetes Research

Clinical investigations focusing on advancing treatment options for patients with Type 2 Diabetes who aren't achieving optimal control with current medications.

  • Therapeutic Focus: Blood glucose management
  • Treatment Combination Studies
  • Metabolic Disease Research

The research evaluates the effectiveness of combining gliclazide MR with existing diabetes medications to improve glycemic control, particularly focusing on HbA1c reduction in patients with inadequate response to current treatments.

02 Metabolic Disorders

Innovative research exploring combination therapy approaches in metabolic disease management, specifically targeting patients with suboptimal response to standard treatments.

  • Medication Optimization
  • Glycemic Control Studies
  • Treatment Enhancement Research

This clinical investigation aims to advance our understanding of treatment optimization for patients requiring additional therapeutic support beyond initial medication regimens.

03 Treatment Efficacy

Comprehensive evaluation of treatment effectiveness in diabetes management, focusing on medication combinations to achieve better patient outcomes.

  • Safety Assessment
  • Clinical Response Monitoring
  • Long-term Effectiveness

The research examines both the efficacy and safety profiles of combined therapeutic approaches over a 24-week period, providing valuable insights into treatment optimization strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.